Listed

Tango Therapeutics, Inc.

TNGXNasdaqCIK 1819133HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$59.8m, Q2 FY2026
Net income−$55.3m, Q2 FY2026
Tango Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m10.7Revenue, Q3 FY2023, three months to 2023-09-30$10.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure5.4Revenue, Q4 FY2023, three months to 2023-12-31$5.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure6.5Revenue, Q1 FY2024, three months to 2024-03-31$6.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure19.9Revenue, Q2 FY2024, three months to 2024-06-30$19.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure11.6Revenue, Q3 FY2024, three months to 2024-09-30$11.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure4.1Revenue, Q4 FY2024, three months to 2024-12-31$4.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure5.4Revenue, Q1 FY2025, three months to 2025-03-31$5.4m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure3.2Revenue, Q2 FY2025, three months to 2025-06-30$3.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure53.8Revenue, Q3 FY2025, three months to 2025-09-30$53.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Research and development$m27.1Research and development, Q3 FY2023, three months to 2023-09-30$27.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure31.3Research and development, Q4 FY2023, three months to 2023-12-31$31.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure38.1Research and development, Q1 FY2024, three months to 2024-03-31$38.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure38.7Research and development, Q2 FY2024, three months to 2024-06-30$38.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure33.3Research and development, Q3 FY2024, three months to 2024-09-30$33.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure33.9Research and development, Q4 FY2024, three months to 2024-12-31$33.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure36.4Research and development, Q1 FY2025, three months to 2025-03-31$36.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure32.8Research and development, Q2 FY2025, three months to 2025-06-30$32.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure30.8Research and development, Q3 FY2025, three months to 2025-09-30$30.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure32.1Research and development, Q4 FY2025, three months to 2025-12-31$32.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure33.5Research and development, Q1 FY2026, three months to 2026-03-31$33.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure37.2Research and development, Q2 FY2026, three months to 2026-06-30$37.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Operating income$m(25.6)Operating income, Q3 FY2023, three months to 2023-09-30−$25.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure(35.0)Operating income, Q4 FY2023, three months to 2023-12-31−$35.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(42.3)Operating income, Q1 FY2024, three months to 2024-03-31−$42.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure(29.6)Operating income, Q2 FY2024, three months to 2024-06-30−$29.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure(32.9)Operating income, Q3 FY2024, three months to 2024-09-30−$32.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(40.9)Operating income, Q4 FY2024, three months to 2024-12-31−$40.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(42.5)Operating income, Q1 FY2025, three months to 2025-03-31−$42.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(41.0)Operating income, Q2 FY2025, three months to 2025-06-30−$41.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure14.1Operating income, Q3 FY2025, three months to 2025-09-30$14.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(41.9)Operating income, Q4 FY2025, three months to 2025-12-31−$41.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(48.8)Operating income, Q1 FY2026, three months to 2026-03-31−$48.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(59.8)Operating income, Q2 FY2026, three months to 2026-06-30−$59.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$23.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$47.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$40.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure0.1Income tax, Q2 FY2024, three months to 2024-06-30$65.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure0.1Income tax, Q3 FY2024, three months to 2024-09-30$54.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$49.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$34.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$35.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure(0.0)Income tax, Q3 FY2025, three months to 2025-09-30−$10.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(0.1)Income tax, Q4 FY2025, three months to 2025-12-31−$55.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$1.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$1.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Net income$m(22.3)Net income, Q3 FY2023, three months to 2023-09-30−$22.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure(30.8)Net income, Q4 FY2023, three months to 2023-12-31−$30.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(37.9)Net income, Q1 FY2024, three months to 2024-03-31−$37.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(25.6)Net income, Q2 FY2024, three months to 2024-06-30−$25.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(29.2)Net income, Q3 FY2024, three months to 2024-09-30−$29.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(37.7)Net income, Q4 FY2024, three months to 2024-12-31−$37.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(39.9)Net income, Q1 FY2025, three months to 2025-03-31−$39.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure(38.9)Net income, Q2 FY2025, three months to 2025-06-30−$38.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure15.9Net income, Q3 FY2025, three months to 2025-09-30$15.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure(38.7)Net income, Q4 FY2025, three months to 2025-12-31−$38.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(45.5)Net income, Q1 FY2026, three months to 2026-03-31−$45.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure(55.3)Net income, Q2 FY2026, three months to 2026-06-30−$55.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Diluted EPS$ per share(0.23)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figurenot reported(0.35)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure(0.24)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure(0.27)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figurenot reported(0.36)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(0.35)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure0.13Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figurenot reported(0.32)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(0.37)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Basic EPS$ per share(0.23)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figurenot reported(0.35)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure(0.24)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure(0.27)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figurenot reported(0.36)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(0.35)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure0.14Basic EPS, Q3 FY2025, three months to 2025-09-30$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figurenot reported(0.32)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(0.37)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure

Balance sheet

Cash and equivalents$345.6m, Q2 FY2026
Shareholders' equity$1.02bn, Q2 FY2026
Tango Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m58.5Cash and equivalents, Q3 FY2023, at 2023-09-30$58.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure66.4Cash and equivalents, FY2023, at 2023-12-31$66.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure61.2Cash and equivalents, Q1 FY2024, at 2024-03-31$61.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure51.6Cash and equivalents, Q2 FY2024, at 2024-06-30$51.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure53.1Cash and equivalents, Q3 FY2024, at 2024-09-30$53.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure69.5Cash and equivalents, FY2024, at 2024-12-31$69.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure58.4Cash and equivalents, Q1 FY2025, at 2025-03-31$58.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure39.3Cash and equivalents, Q2 FY2025, at 2025-06-30$39.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure58.3Cash and equivalents, Q3 FY2025, at 2025-09-30$58.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure112Cash and equivalents, FY2025, at 2025-12-31$112.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure158Cash and equivalents, Q1 FY2026, at 2026-03-31$157.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure346Cash and equivalents, Q2 FY2026, at 2026-06-30$345.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Current assets$m371Current assets, Q3 FY2023, at 2023-09-30$370.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-060682.Report this figure347Current assets, FY2023, at 2023-12-31$346.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028353.Report this figure352Current assets, Q1 FY2024, at 2024-03-31$352.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055065.Report this figure328Current assets, Q2 FY2024, at 2024-06-30$328.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0000950170-24-092274.Report this figure301Current assets, Q3 FY2024, at 2024-09-30$300.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure266Current assets, FY2024, at 2024-12-31$266.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure225Current assets, Q1 FY2025, at 2025-03-31$224.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure190Current assets, Q2 FY2025, at 2025-06-30$190.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure164Current assets, Q3 FY2025, at 2025-09-30$163.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure354Current assets, FY2025, at 2025-12-31$353.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure392Current assets, Q1 FY2026, at 2026-03-31$392.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure1,032Current assets, Q2 FY2026, at 2026-06-30$1.03bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Total assets$m428Total assets, Q3 FY2023, at 2023-09-30$428.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0000950170-23-060682.Report this figure403Total assets, FY2023, at 2023-12-31$402.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-028353.Report this figure406Total assets, Q1 FY2024, at 2024-03-31$406.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000950170-24-055065.Report this figure381Total assets, Q2 FY2024, at 2024-06-30$381.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0000950170-24-092274.Report this figure352Total assets, Q3 FY2024, at 2024-09-30$352.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure316Total assets, FY2024, at 2024-12-31$316.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure274Total assets, Q1 FY2025, at 2025-03-31$274.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure238Total assets, Q2 FY2025, at 2025-06-30$237.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure210Total assets, Q3 FY2025, at 2025-09-30$210.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure399Total assets, FY2025, at 2025-12-31$398.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure436Total assets, Q1 FY2026, at 2026-03-31$435.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure1,074Total assets, Q2 FY2026, at 2026-06-30$1.07bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Current liabilities$m43.4Current liabilities, Q3 FY2023, at 2023-09-30$43.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-060682.Report this figure45.9Current liabilities, FY2023, at 2023-12-31$45.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028353.Report this figure42.8Current liabilities, Q1 FY2024, at 2024-03-31$42.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055065.Report this figure43.9Current liabilities, Q2 FY2024, at 2024-06-30$43.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0000950170-24-092274.Report this figure37.6Current liabilities, Q3 FY2024, at 2024-09-30$37.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure38.2Current liabilities, FY2024, at 2024-12-31$38.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure35.9Current liabilities, Q1 FY2025, at 2025-03-31$35.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure40.0Current liabilities, Q2 FY2025, at 2025-06-30$40.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure18.4Current liabilities, Q3 FY2025, at 2025-09-30$18.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure21.7Current liabilities, FY2025, at 2025-12-31$21.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure14.3Current liabilities, Q1 FY2026, at 2026-03-31$14.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure20.3Current liabilities, Q2 FY2026, at 2026-06-30$20.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Total liabilities$m152Total liabilities, Q3 FY2023, at 2023-09-30$151.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0000950170-23-060682.Report this figure149Total liabilities, FY2023, at 2023-12-31$149.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-028353.Report this figure142Total liabilities, Q1 FY2024, at 2024-03-31$141.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000950170-24-055065.Report this figure134Total liabilities, Q2 FY2024, at 2024-06-30$133.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0000950170-24-092274.Report this figure123Total liabilities, Q3 FY2024, at 2024-09-30$123.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure117Total liabilities, FY2024, at 2024-12-31$117.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure108Total liabilities, Q1 FY2025, at 2025-03-31$107.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure103Total liabilities, Q2 FY2025, at 2025-06-30$102.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure50.1Total liabilities, Q3 FY2025, at 2025-09-30$50.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure52.5Total liabilities, FY2025, at 2025-12-31$52.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure44.3Total liabilities, Q1 FY2026, at 2026-03-31$44.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure49.3Total liabilities, Q2 FY2026, at 2026-06-30$49.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure
Shareholders' equity$m277Shareholders' equity, Q3 FY2023, at 2023-09-30$276.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure253Shareholders' equity, FY2023, at 2023-12-31$253.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-05, accession 0001193125-26-092518.Report this figure264Shareholders' equity, Q1 FY2024, at 2024-03-31$264.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure248Shareholders' equity, Q2 FY2024, at 2024-06-30$247.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure229Shareholders' equity, Q3 FY2024, at 2024-09-30$229.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure200Shareholders' equity, FY2024, at 2024-12-31$199.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure167Shareholders' equity, Q1 FY2025, at 2025-03-31$166.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure135Shareholders' equity, Q2 FY2025, at 2025-06-30$135.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure160Shareholders' equity, Q3 FY2025, at 2025-09-30$160.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure346Shareholders' equity, FY2025, at 2025-12-31$346.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure392Shareholders' equity, Q1 FY2026, at 2026-03-31$391.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure1,025Shareholders' equity, Q2 FY2026, at 2026-06-30$1.02bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure

Cash flow

Operating cash flow−$38.9m, Q2 FY2026
Capital expenditure−$20.0k, Q2 FY2026
Tango Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(31.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$31.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0000950170-24-121818. Derived: 9-month figure less the 6-month figure.Report this figure(27.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(37.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$37.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure(23.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$23.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0000950170-25-102392. Derived: 6-month figure less the 3-month figure.Report this figure(33.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$33.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263680. Derived: 9-month figure less the 6-month figure.Report this figure(36.6)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$36.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(41.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$41.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(36.5)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$36.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-343424. Derived: 6-month figure less the 3-month figure.Report this figure(31.0)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$31.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263680. Derived: 9-month figure less the 6-month figure.Report this figure(29.7)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$29.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(44.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$44.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(38.9)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$38.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-343424. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0000950170-24-121818. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$226.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$195.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure0.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$320.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-05, accession 0000950170-25-102392. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$115.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263680. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$124.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$51.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure0.6Capital expenditure, Q2 FY2025, three months to 2025-06-30$624.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-343424. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$151.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263680. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2025, three months to 2025-12-31$222.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001193125-26-092518. Derived: 12-month figure less the 9-month figure.Report this figure(0.0)Capital expenditure, Q1 FY2026, three months to 2026-03-31−$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure(0.0)Capital expenditure, Q2 FY2026, three months to 2026-06-30−$20.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-343424. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)149.88m, Q2 FY2026
Tango Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares87.9Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3087,892,195 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0000950170-23-060682.Report this figure88.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3188,193,917 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000950170-24-055065.Report this figure88.4Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3088,354,590 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0000950170-24-092274.Report this figure97.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3097,033,273 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0000950170-24-121818.Report this figure108Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31108,171,463 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-068549.Report this figure108Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30108,314,279 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0000950170-25-102392.Report this figure109Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30108,507,390 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure110Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31110,301,256 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure111Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30110,540,836 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure118Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30117,782,074 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001193125-25-263680.Report this figure144Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31143,576,292 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001193125-26-221656.Report this figure150Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30149,875,939 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure

Shares outstanding: 168.61mShares outstanding, period not labelled, at 2026-08-04168,610,367 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343424.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.